HK1202253A1 - 癌症的聯合治療 - Google Patents

癌症的聯合治療

Info

Publication number
HK1202253A1
HK1202253A1 HK15102783.0A HK15102783A HK1202253A1 HK 1202253 A1 HK1202253 A1 HK 1202253A1 HK 15102783 A HK15102783 A HK 15102783A HK 1202253 A1 HK1202253 A1 HK 1202253A1
Authority
HK
Hong Kong
Prior art keywords
cancer
combination treatment
treatment
combination
Prior art date
Application number
HK15102783.0A
Other languages
English (en)
Inventor
Barry Robert Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295082&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1202253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1202253A1 publication Critical patent/HK1202253A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
HK15102783.0A 2011-11-30 2015-03-18 癌症的聯合治療 HK1202253A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564975P 2011-11-30 2011-11-30
PCT/GB2012/052969 WO2013079964A1 (en) 2011-11-30 2012-11-30 Combination treatment of cancer

Publications (1)

Publication Number Publication Date
HK1202253A1 true HK1202253A1 (zh) 2015-09-25

Family

ID=47295082

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102783.0A HK1202253A1 (zh) 2011-11-30 2015-03-18 癌症的聯合治療

Country Status (25)

Country Link
US (2) US20140329786A1 (zh)
EP (1) EP2785349B2 (zh)
JP (1) JP6309454B2 (zh)
KR (1) KR102035361B1 (zh)
CN (1) CN103945849B (zh)
AU (1) AU2012321110B2 (zh)
CA (1) CA2856646C (zh)
CY (1) CY1122624T1 (zh)
DK (1) DK2785349T4 (zh)
ES (1) ES2762250T5 (zh)
FI (1) FI2785349T4 (zh)
HK (1) HK1202253A1 (zh)
HR (1) HRP20191982T4 (zh)
HU (1) HUE046667T2 (zh)
IL (1) IL232530B (zh)
LT (1) LT2785349T (zh)
MX (1) MX367640B (zh)
MY (1) MY175800A (zh)
PL (1) PL2785349T5 (zh)
PT (1) PT2785349T (zh)
RS (1) RS59493B2 (zh)
RU (1) RU2640485C2 (zh)
SG (1) SG11201401471PA (zh)
SI (1) SI2785349T2 (zh)
WO (1) WO2013079964A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
EP2663189B1 (en) 2011-01-11 2018-07-04 Novartis AG Combination of bortezomib with afuresertib and use thereof in the treatment of cancer
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于***性疾病的生物标记物
MX2016004265A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
WO2015116696A1 (en) * 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US11478453B2 (en) 2016-07-21 2022-10-25 Hadasit Medical Research Services And Development Ltd. Treatment for glioblastoma
CN110049765B (zh) * 2016-12-16 2022-02-01 康朴生物医药技术(上海)有限公司 一种组合、其应用及治疗方法
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
AU2018335391A1 (en) * 2017-09-22 2020-03-26 AustinPx, LLC Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (zh) 1963-04-04 1900-01-01
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
JP3711238B2 (ja) 1997-08-05 2005-11-02 ファイザー・プロダクツ・インク 神経ペプチドY受容体アンタゴニストとしての4−アミノピロ−ル(3,2−d)ピリミジン
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α-1肾上腺素能拮抗剂的喹唑啉衍生物
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2002057267A1 (en) 2000-12-01 2002-07-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
US20020182204A1 (en) 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
KR101108722B1 (ko) 2002-01-07 2012-02-17 에자이 알앤드디 매니지먼트 가부시키가이샤 데아자퓨린 및 이의 용도
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
KR20050000544A (ko) 2002-05-17 2005-01-05 아방티 파르마 소시에테 아노님 유방암 및 난소암의 보조 요법에서도세탁셀/독소루비신/사이클로포스파미드의 용도
ES2464157T3 (es) 2002-06-26 2014-05-30 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades causadas por contracción o dilatación vascular
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
AU2003302657B8 (en) 2002-12-04 2009-12-03 Eisai R&D Management Co., Ltd. Fused 1,3-dihydroimidazole ring compounds
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
US20060128956A1 (en) 2003-04-21 2006-06-15 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
KR101169832B1 (ko) 2005-05-13 2012-07-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CN101291659A (zh) 2005-08-31 2008-10-22 阿布拉科斯生物科学有限公司 包含水难溶性药剂和抗微生物剂的组合物
NZ592132A (en) 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
EP2029592A1 (en) 2006-04-25 2009-03-04 Astex Therapeutics Limited Pharmaceutical compounds
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008079346A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
MY150059A (en) * 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
AU2010210422A1 (en) * 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
SG172986A1 (en) * 2009-02-10 2011-08-29 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
WO2011029782A1 (en) * 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
WO2011136828A1 (en) * 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia

Also Published As

Publication number Publication date
US9737540B2 (en) 2017-08-22
MY175800A (en) 2020-07-09
JP6309454B2 (ja) 2018-04-11
SI2785349T2 (sl) 2023-01-31
PL2785349T3 (pl) 2020-03-31
DK2785349T4 (da) 2023-01-09
WO2013079964A1 (en) 2013-06-06
CA2856646C (en) 2020-01-14
NZ625611A (en) 2016-10-28
EP2785349A1 (en) 2014-10-08
JP2015500225A (ja) 2015-01-05
HRP20191982T1 (hr) 2020-02-07
RS59493B1 (sr) 2019-12-31
LT2785349T (lt) 2019-12-10
CN103945849B (zh) 2017-04-26
EP2785349B2 (en) 2022-11-09
CA2856646A1 (en) 2013-06-06
HRP20191982T4 (hr) 2023-01-06
HUE046667T2 (hu) 2020-03-30
RU2014119713A (ru) 2016-01-27
ES2762250T3 (es) 2020-05-22
DK2785349T3 (da) 2020-01-02
KR102035361B1 (ko) 2019-11-08
US20160151373A1 (en) 2016-06-02
EP2785349B1 (en) 2019-10-16
US20140329786A1 (en) 2014-11-06
IL232530A0 (en) 2014-06-30
SI2785349T1 (sl) 2019-12-31
RS59493B2 (sr) 2023-02-28
SG11201401471PA (en) 2014-08-28
BR112014012261A2 (pt) 2017-06-13
AU2012321110B2 (en) 2014-10-23
MX367640B (es) 2019-08-29
RU2640485C2 (ru) 2018-01-09
CN103945849A (zh) 2014-07-23
IL232530B (en) 2018-07-31
CY1122624T1 (el) 2021-03-12
AU2012321110A1 (en) 2013-06-20
KR20140098799A (ko) 2014-08-08
ES2762250T5 (es) 2023-01-05
PT2785349T (pt) 2019-12-11
PL2785349T5 (pl) 2023-01-30
MX2014006547A (es) 2014-07-09
FI2785349T4 (fi) 2023-02-09

Similar Documents

Publication Publication Date Title
HK1202253A1 (zh) 癌症的聯合治療
EP2760452A4 (en) METHODS OF TREATING CANCER
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
SG10201508495VA (en) Combination treatment of cancer
IL232890A0 (en) Immunogenic therapy for cancer
HK1202240A1 (zh) 治療癌症的方法
ZA201307036B (en) Treatment of solid tumours
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
HK1214128A1 (zh) 癌症的治療
IL228430A0 (en) Cancer treatment
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
HK1205254A1 (zh) 治療癌症的方法
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (zh) 癌症治療
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
GB201217890D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201208296D0 (en) Treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer